First-line therapy in atypical hemolytic uremic syndrome: consideration on infants with a poor prognosis

Nóra Szarvas1, Ágnes Szilágyi1, Velibor Tasic2, Valbona Nushi-Stavileci3, Aspazija Sofijanova2, Zoran Gucev2, Miklós Szabó4, Attila Szabó4, Lilla Szeifert4, György Reusz4, Krisztina Rusai5, Klaus Arbeiter5, Thomas Müller5 and Zoltán Prohászka1*

Abstract
Background: Atypical hemolytic uremic syndrome (aHUS) is a rare and heterogeneous disorder. The first line treatment of aHUS is plasma therapy, but in the past few years, the recommendations have changed greatly with the advent of eculizumab, a humanized monoclonal anti C5-antibody. Although recent recommendations suggest using it as a primary treatment for aHUS, important questions have arisen about the necessity of immediate use of eculizumab in all cases. We aimed to draw attention to a specific subgroup of aHUS patients with rapid disease progression and high mortality, in whom plasma therapy may not be feasible.

Methods: We present three pediatric patients of acute complement-mediated HUS with a fatal outcome. Classical and alternative complement pathway activity, levels of complement factors C3, C4, H, B and I, as well as of anti-factor H autoantibody and of ADAMTS13 activity were determined. The coding regions of CFH, CFI, CD46, THBD, CFB and C3 genes were sequenced and the copy number of CFI, CD46, CFH and related genes were analyzed.

Results: We found severe activation and consumption of complement components in these patients, furthermore, in one patient we identified a previously not reported mutation in CFH (Ser722Stop), supporting the diagnosis of complement-mediated HUS. These patients were not responsive to the FFP therapy, and all cases had fatal outcome.

Conclusion: Taking the heterogeneity and the variable prognosis of atypical HUS into account, we suggest that the immediate use of eculizumab should be considered as first-line therapy in certain small children with complement dysregulation.

Keywords: Atypical hemolytic uremic syndrome, Infant, Eculizumab, Plasma therapy

Background
Hemolytic uremic syndrome (HUS) defined by hemolytic anemia, thrombocytopenia, and acute renal failure belongs to the group of thrombotic microangiopathies (TMA) [1]. In the majority of cases Shiga toxin-producing bacteria cause HUS, which is also known as ‘typical’ HUS with a good prognosis and without relapses. However, less often the disease follows a relapsing course with high risk of permanent renal damage or even death [2,3]. In the majority of these cases with this ‘atypical’ HUS (aHUS), severe dysregulation of the alternative complement pathway can be detected, although, there are exceptions to this rule. Mutations, risk haplotypes, and copy-number variations in the genes encoding complement factors (such as complement factor H, membrane cofactor protein, complement factor I, complement C3, complement factor B or thrombomodulin) [1,2,4], and the presence of factor H autoantibodies [5] associated with the homozygous deletion of the complement factor H-related gene 1 [6] have been described as predisposing factors for aHUS [1,2,4]. Much less is known about the pathogenesis of the non-complement-mediated forms of aHUS; however, a recent study, applying a next-generation sequencing-based
approach has identified the variations of diacyl-glycerol kinase epsilon as a novel risk factor in such patients [7].

According to the 2009 guideline of the European Pediatric Study Group for HUS [3], the first-line treatment of atypical HUS – i.e. HUS not mediated by enterohemorrhagic *E. coli* (EHEC), and not associated with *Streptococcus pneumoniae* – should be plasma therapy (plasma exchange or plasma infusions) with early assessment of the clinical response. However, in the past few years new prospects have opened in the management of aHUS with the advent of eculizumab. This humanized monoclonal anti C5-antibody, licensed for the treatment of patients with aHUS in the US in September 2011, and in the EU in November 2011, inhibits C5, thereby preventing the generation of C5a and of the terminal complement complex C5b-9. Recently published clinical trials confirmed the efficacy and safety of eculizumab in plasma-dependent aHUS patients and in posttransplant aHUS recurrence [8,9], and a trial has been applied eculizumab as the first-line treatment of aHUS [10]. The availability of eculizumab has increased noticeably during the past few years, and recent recommendations based on the above trials, case reports [11] and recent case series [12] suggest its administration as a primary treatment for patients with aHUS [13]. Recently, however, Ruebner and co-workers have raised an important question about the necessity of eculizumab in aHUS with the advent of eculizumab. This humanized monoclonal anti C5-antibody, licensed for the treatment of patients with aHUS in the US in September 2011, and in the EU in November 2011, inhibits C5, thereby preventing the generation of C5a and of the terminal complement complex C5b-9. Recently published clinical trials confirmed the efficacy and safety of eculizumab in plasma-dependent aHUS patients and in posttransplant aHUS recurrence [8,9], and a trial has been applied eculizumab as the first-line treatment of aHUS [10]. The availability of eculizumab has increased noticeably during the past few years, and recent recommendations based on the above trials, case reports [11] and recent case series [12] suggest its administration as a primary treatment for patients with aHUS [13]. Recently, however, Ruebner and co-workers have raised an important question about the necessity of eculizumab in aHUS. The authors highlighted the heterogeneity of aHUS and described the illustrative case histories of three children aged less than 18 years with this condition. These patients proved responsive to plasma therapy and made full recovery. The authors recommended a stepwise approach to the management of patients with the aHUS phenotype, and suggested administering eculizumab only to patients likely to have an inherited, complement-mediated disorder and in cases without a good response to plasma therapy after 3–5 days.

While agreeing with this opinion, we would like to draw attention to a specific subgroup of patients with rapidly progressive disease and a poor prognosis, in whom plasma exchange or effective plasma therapy may not be feasible due to young age and small body size. We review the cases of three infants to show that for such patients, prompt treatment with eculizumab would be indicated and urgent complement testing may guide immediate therapeutic decisions.

**Patients and methods**

**Patient selection**

From January 2008 to June 2013, we investigated 5 patients under the age of 2 years with suspected atypical HUS (non-EHEC-mediated, non-pneumococcal disease). Blood samples obtained during the first acute phase were available from only three infants.

In this study, we present case histories of these selected infants (a 7 month old boy from Kossovo, a newborn from Hungary, and a 2 month old girl from Austria) with complement mediated aHUS and fatal outcome during the first disease flare. Relevant clinical and laboratory data were collected from hospital records. The institutional review board of Semmelweis University approved the design of the study.

**Laboratory analysis**

Blood samples were collected during the first acute disease flare. Functional assessment of the activity of the alternative and classical complement pathways was performed along with the measurement of the concentrations of complement factors C3, C4, H, B and I, as well as of anti-factor H IgG autoantibodies, and of ADAMTS13 activity. These laboratory determinations have been described in detail elsewhere [15,16].

To measure the levels of factor H protein (as well as of CFHL-1 protein) variants containing tyrosine (p.Tyr402) or histidine (p.His402) at p.402, serum sample of patient 1 was tested with an allele-specific ELISA method using a HK353 ELISA kit (Hycult Biotech), according to the manufacturer’s instructions.

To screen for mutations, all coding exons of the genes encoding complement factor H (*CFH*), factor I (*CFI*), membrane cofactor protein (*CD46*), thrombomodulin (*THBD*), factor B (*CFB*), C3 (*C3*) and diacyl-glycerol kinase epsilon (*DGKE*) were sequenced following PCR amplification. Primer sequences and PCR conditions are available upon request.

To study the copy number alterations of the genes encoding complement factor H (*CFH*) and related genes (*CFHR1*, *CFHR2*, *CFHR3*, *CFHR5*), complement factor I (*CFI*) and membrane cofactor protein (*CD46*) multiplex ligation-dependent probe amplification (MLPA) was carried out by SALSA MLPA probemixes P236-A3 and P296-A1 (MRC-Holland, Amsterdam, The Netherlands) following the manufacturer’s instructions.

**Results**

**Patient 1 (Registry code 193)**

The male patient was born in Kosovo at week 39 of an uncomplicated pregnancy, with a birth weight of 3400 g. At the age of 7 months, he was taken to the Children’s Hospital in Prishtina due to sudden onset of pallor, weakness, and anemia. There was neither fever, nor diarrhea. His initial laboratory findings (see Table 1) showed severe anemia and thrombocytopenia with normal renal function and diuresis. Direct antiglobulin test was negative.

He was initially considered to have sepsis and was given antibiotic treatment. He received packed red blood cells and fresh frozen plasma transfusions on three
occasions. His hematological parameters improved, but on day 10 of hospitalization, his renal function deteriorated rapidly. He became anuric and decompensated dilated cardiopathy developed, which required hospitalization at the University Children’s Hospital Skopje, for peritoneal dialysis.

Atypical HUS was suspected, but (after plasma therapy) his hematological parameters were inconclusive (haemoglobin level and platelet count were normal) on admission. Fragmented red blood cells could not be demonstrated even by repeated blood smear analysis, and complement C3 level was normal at 0.90 g/L. Peritoneal dialysis improved the patient’s clinical condition and cardiac function. His creatinine level peaked at 316 μmol/L.

On day 19 of hospitalization, his overall condition worsened, severe anemia and seizures occurred. This time, blood smear analysis revealed many schistocytes. Follow-up laboratory tests confirmed the relapse of severe anemia and thrombocytopenia. At this point, the clinical diagnosis of atypical HUS was certain and appropriate blood samples were sent to Hungary for the comprehensive analysis of complement factors. These blood samples, received 24 days after disease onset and after plasma therapy, were tested on the day of arrival of sample for C3, alternative pathway and ADAMTS13 activity, and the results indicated severe complement dysregulation.

The patient was intubated and mechanically ventilated, transfused on three occasions with packed red blood cells and fresh frozen plasma. Despite intensive therapy and the administration of plasma, the baby fell into coma. Respiratory failure accompanied by symptomatic multiorgan failure led to the patient’s death on day 29 of hospitalization. Autopsy was not performed.

### Patient 2 (Registry code 229)

The male neonate was born in Hungary, from an uneventful pregnancy and delivered by the vaginal route, at 36 weeks of gestation, with a birth weight of 2150 g.

On the second day of life, poor feeding, abdominal distension, hepatomegaly, respiratory distress were observed along with reduced skin perfusion and oliguria despite normal blood pressure. Bacterial sepsis was suspected and antibiotic treatment was introduced.

The laboratory tests showed anemia, low platelet count, and metabolic acidosis, as well as bleeding disorder (increased INR; fibrinogen: under detection limit), and a marked elevation of LDH. However, no hyperbilirubinemia was present. On the 4th day of life, uremia, low platelet count, and metabolic acidosis persisted, and moderate increase of alanine aminotransferase and aspartate aminotransferase levels were seen. Direct anti-globulin test was negative.

Progressive circulatory failure required mechanical ventilation and catecholamine treatment from the 4th day of life. Echocardiography depicted a haemodynamically significant, patent ductus arteriosus. The differential diagnosis excluded bacterial sepsis, renal vein thrombosis, and metabolic disorder. The treatment was supplemented with regular, periodic administration of fresh frozen plasma, based on the clinical signs and laboratory results indicative of aHUS.

Progressive circulatory failure, oliguria and uremia culminated in extreme volume overload and pulmonary edema. Therefore, hemofiltration was started on the 9th day of life and repeated altogether 7 times. Despite all these efforts, the patient did not improve and died on the 19th day of life of circulatory failure unresponsive to the treatment.

### Table 1 Laboratory findings at the time when aHUS was confirmed

|                  | Patient 1 | Patient 2 | Patient 3 |
|------------------|-----------|-----------|-----------|
| Age              | 7 months  | 2 days    | 2 months  |
| Gender           | Male      | Male      | Female    |
| Hemoglobin (g/L) | 69 (120–160) | 122 (100–160) | 83 (120–150) |
| Platelet count (G/L) | 26 (150–400) | 65 (130–450) | 28 (140–440) |
| LDH (U/L)        | 13500 (<500) | 4826 (200–800) | 5230 (100–300) |
| Creatinine (µmol/L) | 316 (<88) | 182 (20–105) | 98 (8,8–88) |
| Fragmentocytes   | +         | +         | -         |
| RBC transfusion (Unit) | 6 times  | 2 times   | -         |
| Plasma therapy (number of sessions) | FFP (6) | FFP (9) | FFP (1) |
| Dialysis (sessions) | 15       | 7         | 2         |
| Outcome          | Seizures, coma and respiratory failure, death on day 29 of hospitalization | Pulmonary edema and pneumothorax, death on day 17 of hospitalization | Cerebral edema, brain death on day 3 of hospitalization |
| Comorbidities    | -         | Patent ductus arteriosus | Colonic necrosis, coagulopathy |

Normal values are between brackets.
The serum complement profile obtained on day 14 showed alternative pathway dysregulation and supported the diagnosis of aHUS. Investigations during autopsy could not identify any alternative (infective or malignant) causes of HUS. The histological examination of the kidney and the lung revealed signs of small vessel microangiopathy (thickening of capillary walls, lamellation, detachment of endothelial cells, narrowing of the capillary lumen).

**Patient 3 (Registry code 304)**
The female infant was born in Austria, at 38 weeks of gestation with a birth weight of 3750 g. The antenatal and perinatal periods were uneventful.

At the age of 2 months, she developed acute abdominal distension and cyanosis. There was no history of infection, vomiting, or diarrhea in the previous days.

Initial laboratory findings included high LDH, CK, and serum transaminase levels. Serum albumin concentration was greatly reduced. INR, PTT, and thrombin time were prolonged, C-reactive protein was normal; interleukin-8 level and the leukocyte count were elevated. Renal function parameters, platelet count, and hemoglobin were normal on day 1.

Abdominal ultrasound showed massive edema of the bowels, particularly of the colon and the duodenum. A plain abdominal film did not depict any sign of free air. The progressive decline of oxygen saturation and worsening respiratory insufficiency necessitated respiratory support and then, intubation and mechanical ventilation.

During the next hours, oliguria progressed to anuria, and generalised edema developed. Simultaneously, platelet count and hemoglobin level decreased, whereas renal function parameters increased. Peritoneal dialysis was initiated on day 2 due to progressive edema and renal insufficiency. The follow-up laboratory tests showed further elevation of the LDH level. Complement dysregulation was detected on day 2 (Table 2). The direct antithrombin test was negative; haptoglobin level was decreased, and free hemoglobin concentration was increased in the plasma. These findings indicated intravascular hemolysis; however, fragmentocytes were absent from the blood smear. Irreversible multiorgan failure developed during the next hours; the CT scan confirmed generalized brain edema, while further testing excluded underlying infectious and/or metabolic causes of the multiorgan failure. The patient died on day 3.

Investigations during autopsy could not identify any alternative (infective or malignant) causes of HUS. The histological examination of the kidney, spleen, lung, bowel, and myocardium confirmed thrombotic microangiopathy.

**The results of complement- and genetic testing**
The detailed results of complement profiling are presented in Table 2. Alternative complement pathway activity was decreased in all three patients. The consumption of C3, as well as decreased levels of complement factor B and I were found in all cases. Factor H level was below the detection limit in patient 1 and 3, and it was decreased in patient 2. The level of C4 and the activity of the classical pathway were decreased in patients 2 and 3. Since we observed unusual concomitant decrease in these factors in patients 2 and 3, we have measured the levels of potassium, magnesium, calcium and phosphate in these serum samples and none of them was decreased excluding the possibility that samples were diluted with infusion.

ADAMTS13 activity was decreased but not deficient in all cases, and the presence of the ADAMTS13 inhibitor was excluded in two cases (Table 2). None of the family members had low (<67%) ADAMTS13 level indicative of ADAMTS13 deficiency. We suspect secondary ADAMTS13 consumption by the ultra-large von Willebrand factor due to extensive endothelial activation.

All patients were negative for anti-factor H autoantibody. Regarding the family members of patients, no signs of complement deficiency or dysregulation was detected in the family of patient 1. The father of patient 2 had low levels of factor B, I and C3, the father of patient 3 had below normal level of factor B, while other family members in these families had normal complement parameters.

To investigate the genetic alterations in our patients, we sequenced the coding regions of complement genes *CFH, CFI, CD46, THBD, CFB, C3 and DGKE*. Patient 1 was heterozygous for a cytosine to adenine substitution (c.2165C>A) in exon 15 of *CFH* (encoding short consensus repeat 12) that causes a serine to STOP change at p.722 (Ser722Stop) in the protein. Mutation at this site has not been reported previously. Based on the analysis of inheritance in the patient’s family, this mutation was located on an allele coding histidine at p.402. As the patient was heterozygous for the Tyr402His (Y402H) polymorphism, we applied an ELISA test system using two different monoclonal antibodies, specific for the His402- and Tyr402- containing factor H proteins (HK353 ELISA kit, Hycult Biotech). The level of factor H protein from the Ser722Stop mutation-containing allele (p.402His-containing factor H) was below the lower limit of quantification, while the level of factor H from the other allele (p.402Tyr-containing factor H) was low, but still measurable in the serum sample of the patient. The mutation-carrying father of the patient was not heterozygous for the Tyr402His polymorphism, therefore there are no comparable alleles in his serum, so we did not apply this method in this case. Based on these results we concluded that the mutation p.Ser722Stop by causing the premature termination of translation presumably leads to deficient synthesis and/or secretion of the mutated protein. No disease-causing mutation was detected in the other two patients.
Table 2 Complement and genetic profiles of the members of the three affected families

|                       | Patient 1 | Father 1 | Mother 1 | Sister 1 | Patient 2 | Father 2 | Mother 2 | Patient 3 | Father 3 | Mother 3 | Brother 3 | Sister 3 |
|-----------------------|-----------|----------|----------|----------|-----------|----------|----------|-----------|----------|----------|-----------|----------|
| **Classical pathway** |           |          |          |          |           |          |          |           |          |          |           |          |
| activity CH50/mL (48–103) | 47        | n.d.     | n.d.     | n.d.     | 25        | n.d.     | n.d.     | 0         | n.d.     | n.d.     | n.d.     | n.d.     |
| **Alternative pathway** |           |          |          |          |           |          |          |           |          |          |           |          |
| activity % (70–105)   | 5         | 88       | 97       | 108      | 0         | 71       | 77       | 0         | 106      | 110      | 70        | 72       |
| C3 g/L (0.9–1.8)      | 0.36      | 0.98     | 1.32     | 1.23     | 0.26      | 0.65     | 1.19     | 0.41      | 1.26     | 1.42     | 1.07      | 1.09     |
| C4 g/L (0.15–0.55)    | 0.23      | n.d.     | n.d.     | n.d.     | 0.1       | n.d.     | n.d.     | 0.05      | n.d.     | n.d.     | n.d.     | n.d.     |
| Factor H Ag mg/L (250-880) | <95     | 378      | 813      | 631      | 123       | 369      | 549      | <95       | 374      | 685      | 431       | 338      |
| Factor B % (70–130)   | 65        | 81       | 98       | 90       | 50        | 52       | 100      | 19        | 60       | 98       | 70        | 90       |
| Factor I % (70–130)   | 42        | 108      | 108      | 104      | 47        | 69       | 112      | 26        | 85       | 112      | 72        | 81       |
| Anti-factor H IgG autoantibody | negative | n.d.     | n.d.     | n.d.     | negative | n.d.     | n.d.     | negative | n.d.     | n.d.     | n.d.     | n.d.     |
| ADAMTS13 activity (67-151%) | 27       | 214.     | 143      | 171      | 9         | 133      | 101      | 8         | 124      | 112      | 142       | 157      |
| ADAMTS13 inhibitor | negative | n.d.     | n.d.     | n.d.     | n.d.     | n.d.     | n.d.     | negative | n.d.     | n.d.     | n.d.     | n.d.     |
| Mutation (Numbering from Met1) |               |          |          |          |           |          |          |           |          |          |           |          |
| het CFH Ser722Stop | -         | -        | -        | -        | -         | -        | -        | -         | -        | -        | -         | -        |
| het CFH Y402H; het MCPgaac | -         | -        | -        | -        | -         | -        | -        | -         | -        | -        | -         | -        |
| hom CFH Y402H; het CFH Y402H; | -         | -        | -        | -        | -         | -        | -        | -         | -        | -        | -         | -        |
| het CFH V62I, hom CFH Y402H; | -         | -        | -        | -        | -         | -        | -        | -         | -        | -        | -         | -        |
| het CFH E936D, het CFH E936D; | -         | -        | -        | -        | -         | -        | -        | -         | -        | -        | -         | -        |
| hom CFH V62I, hom CFH Y402H; | -         | -        | -        | -        | -         | -        | -        | -         | -        | -        | -         | -        |
| het CFH E936D; het CFH E936D; | -         | -        | -        | -        | -         | -        | -        | -         | -        | -        | -         | -        |
| hom CFH V62I, hom CFH Y402H; | -         | -        | -        | -        | -         | -        | -        | -         | -        | -        | -         | -        |
| het CFH E936D; het CFH E936D; | -         | -        | -        | -        | -         | -        | -        | -         | -        | -        | -         | -        |
| hom CFH V62I, hom CFH Y402H; | -         | -        | -        | -        | -         | -        | -        | -         | -        | -        | -         | -        |
| het CFH E936D; het CFH E936D; | -         | -        | -        | -        | -         | -        | -        | -         | -        | -        | -         | -        |
| hom CFH V62I, hom CFH Y402H; | -         | -        | -        | -        | -         | -        | -        | -         | -        | -        | -         | -        |
| *Abbreviations used:* het heterozygous, hom homozygous, n.d. not determined, bold characters indicate values below the reference range.
Sequencing of the selected complement genes revealed the presence of multiple polymorphic variants. As inferred from genotype data, one patient (patient 1) carried the H3 risk haplotype of the CFH gene, and two patients (patient 1 and patient 3) carried risk alleles of MCP polymorphisms (MCPggaac). The results of the pedigree analysis are presented in Table 2.

To reveal deletions or duplications that may influence disease development, CFI, CD46 (MCP) as well as CFH and its related genes were studied by applying MLPA probemixes of MRC-Holland. None of the patients showed copy number alterations in the selected genes.

Discussion
Recent findings on the pathogenesis and the new therapeutic options have markedly changed the recommendations on the initial investigations and therapy of choice in aHUS. However, a number of questions remain open regarding the optimal management of patients with aHUS. The clinical classification of HUS as atypical HUS is based on the clinical signs (see the 2009 guideline), and the recognition of HUS in the context of sepsis or disseminated intravascular coagulation is often delayed, because anemia and thrombocytopenia are characteristic of both diseases. Plasma therapy may interfere with the laboratory tests used to support aHUS and can thereby delay correct diagnosis. However, initial complement results may be helpful and these can be obtained within 1–2 days. According to the Clinical Practice Guidelines for the management of aHUS, detailed complement investigation is recommended in all cases at the onset of the episodes, before administering plasma therapy. To explore the complement-related pathogenetic factors, it is suggested to test the serum levels of C3, C4 (for differential diagnosis), factor I and factor H, as well as of autoantibodies to factor H and MCP expression on leukocytes. The genetic analysis of selected complement factors should also be performed. During the recent years, we added two more tests to the diagnostic evaluation of the alternative complement pathway, i.e. the measurement of total AP activity, and of factor B level. According to our previous results, multiple assessment of the components and total activity of the alternative pathway (decreased C3, factor B and alternative pathway activity) appears to yield specific information on complement-mediated processes in aHUS.

In this small series of cases with clinically diagnosed aHUS, all patients had decreased alternative pathway activity with consumption of factors C3 and B, as well as with unusually low levels of factors H and I, indicating extensive amplification and consumption of the alternative pathway with its regulators. In our opinion, all three patients had complement-mediated HUS, as all of them presented with hemolytic anemia, thrombocytopenia and acute renal failure (Figure 1). Moreover, severe dysregulation and consumption of the alternative complement pathway could be verified within a day after the arrival of the blood sample to the laboratory. It should be noted, however, that the marked decrease of classical pathway activity, C4 levels, and ADAMTS13 activity in our cases indicates an uncommon pathogenetic mechanism (most likely induced by yet unidentified genetic predisposing factors in cases 2 and 3). Low but not deficient ADAMTS13 level of patients besides the absence of ADAMTS13 inhibitors (where measured) excluded the diagnosis of TTP, while based on the normal levels of ADAMTS13 activity of the healthy family members we ruled out the possibility of Upshaw-Schulman syndrome. Furthermore, unidentified, alternative causes of HUS, such as infectious, malignant, immunologic, or metabolic diseases may also be suspected in our patients. However, the fact that no such diseases were found during autopsy in patients 2 and 3, renders this possibility improbable. The findings of the histological investigations performed during autopsy supported the diagnosis of TMA in patients 2 and 3. Therefore we consider that complement mediated HUS was the primary diagnosis in these cases. Since signs of coagulation disorder were also present disseminated intravascular coagulation accompanied aHUS in patients 2 and 3.

Analyzing the predisposing genetic components within complement factors, we identified combined risk factors (factor H mutation Ser722Stop and two risk haplotypes in CFH and MCP) for patient 1, and non-synonymous SNPs (in C3 or CFB) and/or aHUS risk haplotype (MCPggaac) for patients 2 and 3. In approximately 40-50% of aHUS cases, no mutations can be identified in the complement genes. The missense polymorphisms of C3 (rs2230199: R102G, rs1047286: P314L) and factor B (rs4151667: L9H and rs12614: R32W) identified in the patients has unknown significance in aHUS. However, carriers of the rare alleles of the R102G SNP and of the P314L polymorphism as well as of their haplotype were reported to have lower AP50 values (higher alternative pathway activity) than those with homozygous wild genotypes. In agreement with this, in hemolysis assays G102 activated the alternative pathway more efficiently and had higher hemolytic activity compared with the R102 C3 protein as the alternative pathway more efficiently and had higher AP50 values (higher alternative pathway activity) than those with homozygous wild genotypes.

Since decreased levels of complement parameters (predominantly factor B) were observed in healthy family members (i.e. in the father of patients 2 and 3), we suspect...
additional predisposing genetic variants in the background of the disease [4].

Since the publication of the “European Guideline for the investigation and initial therapy of HUS” significant progress has been made in the therapy of HUS with the clinical verification of the efficacy of eculizumab [8], an anti-C5 monoclonal antibody based inhibitor of the complement terminal pathway. Physicians treating patients with atypical HUS have to choose between plasma therapy and eculizumab for the initial treatment of acute disease.

Although the guidelines recommend plasma exchange [1,3], low total blood volume and difficult vascular access make plasmapheresis technically challenging in infants; therefore, this therapeutic option is seldom used [21,22]. Fresh frozen plasma transfusion is an alternative option, but this treatment will not eliminate potentially harmful components and as in our cases, patients often do not respond to FFP. Moreover, mortality rate appears to be the highest in patients under 2 years [19,23]. Based on a recent paper, there were 9 cases with fatal outcome and 6 of them were under 2 years of age in the French cohort. In the Dutch cohort, only the youngest patient in the study, a one month old baby died during the first aHUS episode. In accordance with these data, we have also observed a high mortality rate in this age group: altogether 4 of our 5 infant patients died under the age of 1 (unpublished data).

We report these patients to draw attention to a plasma-resistant disease subtype with a severe outcome in infants. We believe that eculizumab might have saved the lives of our patients, but this therapy could not be started fast enough in our cases due to its high price (in Hungary), its unavailability (in Macedonia), or because...
of the rapid progression of disease (in Austria). Previously, other reports confirmed that eculizumab could be an effective therapy for infants with aHUS of rapidly progressive onset, when plasmapheresis is not feasible [10,24–26]. In agreement with these recommendations [10,17,26], we also suggest that eculizumab should be the first-line therapy for infants with hypocomplementemia accompanied by the clinical symptoms of aHUS. Treatment should start immediately when clinical diagnosis of HUS can be verified and the atypical form is suspected [3]. A recently published paper proposed a stepwise approach for the management of aHUS [14]. This would be appropriate for most patients; however, in the case of infants, we would not be willing to wait 3–5 days to assess the patient’s response to plasma therapy. Urgent investigation of the alternative complement pathway is appropriate to stratify patients for eculizumab therapy. Therefore, in agreement with a recent recommendation [17], we would suggest prompt treatment with eculizumab in small pediatric cases, once complement dysregulation has been recognized.

Conclusion
Infants constitute a specific subgroup of atypical HUS patients, with rapid disease progression and high mortality, in whom plasma therapy may not be feasible. The use of eculizumab should be considered as first-line therapy in these pediatric cases. Urgent investigation of the alternative complement pathway is suitable to stratify patients for eculizumab therapy. We would suggest that the treatment should start immediately, once the diagnosis of HUS has been verified and the atypical form is suspected.

Consent
The parents of patients gave their consent to the publication of the report.

Competing interests
The authors declare that they have no competing interest.

Authors’ contributions
NS, AS: genetic analysis, drafting the article, final approval of the version to be published. VT, VNS, AS, ZGC: medical attendance of patient1 and family1, drafting paragraph ‘patient1’, revising the manuscript, final approval of the version to be published. MS, AS, LS, GR: medical attendance of patient2 and family2, drafting paragraph ‘patient2’, revising the manuscript, final approval of the version to be published. KR, KA, TM: medical attendance of patient3 and family3, drafting paragraph ‘patient3’, revising the manuscript, final approval of the version to be published. ZP: complement measurements, analysis and interpretation of data, revising the manuscript, final approval of the version to be published.

Acknowledgement
The authors are grateful for the excellent technical support from Beáta Takács, Dorottya Csuka, Edina Szabó, György Sinkovits, Antalné Szígeyi, Márta Kókai, Zsuzsanna Szendrei, and Rudolfné Holéczy.

The study was financially supported by a grant from National Research Fund of Hungary (T100687 to ZP).

Author details
1 3rd Department of Internal Medicine, Semmelweis University, Kútvölgyi st. 4, H-1125 Budapest, Hungary. 2 Department of Pediatric Nephrology, University Children’s Hospital, Skopje, Macedonia. 3 Department of Nephrology, Pediatric Clinic, University Clinical Centre of Kosova, Pristina, Republic of Kosovo. 4 1st Department of Pediatrics, Semmelweis University, Budapest, Hungary. 5 Department of Pediatrics, Medical University Vienna, Vienna, Austria.

Received: 15 September 2014 Accepted: 2 December 2014
Published online: 11 December 2014

References
1. Loirat C, Fremeaux-Bacchi V: Atypical hemolytic uremic syndrome. Orphanet J Rare Dis 2011, 6:60.
2. Caprioli J, Noris M, Brioschi S, Panetti G, Castelletti F, Bettinaglio P, Mele C, Besin E, Cassis L, Gamba S, Porrati F, Bucchioni S, Montefrancone G, Fang CJ, Liszewski MK, Kavanagh D, Atkinson JP, Remuzzi G: International Registry of Recurrent and Familial HUS/TP. Genetics of HUS: the impact of MCP, CFH, and IF mutations on clinical presentation, response to treatment, and outcome. Blood 2006, 108:1267–1279.
3. Arcieta G, Besbo N, Johnson S, Karpman D, Landau D, Licht C, Loirat C, Pecoraro C, Taylor CM, Van de Velden M, Zierz-Zittersack LB, European Paediatric Study Group for HUS: Guideline for the investigation and initial therapy of diarrhoea-negative hemolytic uremic syndrome. Pediatr Nephrol 2009, 24:687–696.
4. Kavanagh D, Goodship T: Genetics and complement in atypical HUS. Pediatr Nephrol 2010, 25:2431–2442.
5. Dragon-Durey MA, Loirat C, Cloarec S, Machet MA, Blond J, Nivet H, Weiss L, Fridman WH, Fremeaux-Bacchi V: Anti-Factor H autoantibodies associated with atypical hemolytic uremic syndrome. J Am Soc Nephrol 2005, 16:555–563.
6. Jozi M, Licht C, Strobel S, Ziepl S, Richter H, Heinlen S, Ziepl P, Skerka C: Factor H autoantibodies in atypical hemolytic uremic syndrome correlate with CFHR1/CFHR3 deficiency. Blood 2008, 111:1512–1514.
7. Lemaire M, Fremeaux-Bacchi V, Schaefer F, Choi M, Tang WH, Le Quinrec M, Fakhouri F, Taque S, Nobili F, Martinez F, Ji W, Overton JD, Man E, Nürnberg G, Altmüller J, Thiele H, Morin D, Deschenes G, Bau douvin V, Llanas B, Collard L, Majid MA, Simkova E, Nürnberg P, Rioux-Leclerc N, Moeckel GW, Gubler MC, Hwa J, Loirat C, Lifton RP: Recurrent mutations in DGKE cause atypical hemolytic-uremic syndrome. Nat Genet 2013, 45:531–536.
8. Legendre CM, Licht C, Muus P, Greenbaum LA, Babu S, Bedrosian C, Bingham C, Cohen DJ, Delmas Y, Douglas K, Etter F, Feldkamp T, Fouque D, Furman RR, Gaber O, Hertheils M, Hourmant M, Karpman D, Lebrun Y, Marat C, Menje J, Moulin B, Nürnberg J, O’Gawa M, Remuzzi G, Richard T, Sbrero-Sousan R, Severino B, Sheerin NS, Trivelli A, et al: Terminal complement component inhibitor eculizumab in atypical hemolytic-uremic syndrome. N Engl J Med 2013, 368:2169–2181.
9. Zuber J, Le Quinrec M, Krud S, Bertoye C, Gueutin V, Lahoche A, Heyne N, Ardissino G, Chatelvet V, Noel LH, Hourmant M, Niaudet P, Frèmeaux-Bacchi V, Rondeau E, Legendre C, Loirat C, French Study Group for Atypical HUS: Eculizumab for atypical hemolytic uremic syndrome recurrence in renal transplantation. Am J Transplant 2012, 12:3357–3359.
10. Christmann M, Hansen M, Bergmann C, Schwabe D, Brand J, Schneider W: Eculizumab as first-line therapy for atypical hemolytic uremic syndrome. Pediatrics 2014, 133:e1759–e1763.
11. Zuber J, Fakhouri F, Roumenina LT, Loirat C, Fremeaux-Bacchi V: Use of eculizumab for atypical haemolytic uraemic syndrome and C3 glomerulopathies. Nat Rev Nephrol 2012, 8:643–657.
12. Fakhouri F, Delmas Y, Pirozot F, Barbet C, Karras A, Védranss A, Malikarsi R, Courvaud C, Réfard K, Servais A, Allard C, Besson V, Cousin M, Chatelvet V, Goujon JM, Coinudre JP, Laurent G, Loirat C, Frémeaux-Bacchi V: Insights from the use in clinical practice of eculizumab in adult patients with atypical hemolytic uremic syndrome affecting the native kidneys: an analysis of 19 cases. Am J Kidney Dis 2014, 63:40–48.
13. Campistol JM, Arias M, Arcieta G, Blasco M, Espinosa M, Grinyó JM, Praga M, Torra R, Villada R, Rodríguez De Cordoba S: An update for atypical haemolytic uraemic syndrome: diagnosis and treatment. A consensus document. Nefrologia 2013, 33:27–45.
14. Ruebner RL, Kaplan BS, Copelovitch L: A time for reappraisal of “atypical” hemolytic uremic syndrome: should all patients be treated the same? Eur J Pediatr 2012, 171:1519–1525.
15. Reti M, Farkas P, Csuka D, Razso K, Schlammadinger A, Udvardy Ml, Madach K, Domjan G, Bereczki C, Reusz GS, Szabó AJ, Prohászka Z. Complement activation in thrombotic thrombocytopenic purpura. J Thromb Haemost 2012, 10:791–798.

16. Szilágyi A, Kiss N, Bereczki C, Talosi G, Racz K, Tuši S, Gyorke Z, Simon E, Horváth E, Kelen K, Reusz GS, Szabó AJ, Tulasay T, Prohászka Z. The role of complement in Streptococcus pneumoniae-associated haemolytic uremic syndrome. Nephrol Dial Transplant 2013, 28:2237–2245.

17. Fakhouri F, Fremeaux-Bacchi V, Loria C. Atypical hemolytic uremic syndrome: from the rediscovery of complement to targeted therapy. Eur J Intern Med 2013, 24:492–495.

18. Prohaszka Z, Varga L, Fust G. The use of ‘real-time’ complement analysis to differentiate atypical haemolytic uremic syndrome from other forms of thrombotic microangiopathies. Br J Haematol 2012, 158:424–425.

19. Heurich M, Martinez-Barricarte R, Francis NJ, Roberts DL, Rodriguez de Cordoba S, Morgan BP, Harris CL. Common polymorphisms in C3, factor B, and factor H collaborate to determine systemic complement activity and disease risk. Proc Natl Acad Sci U S A 2011, 108:8761–8766.

20. Abero-Abelela MA, Nishimura C, Frees K, Jones M, Maga T, Katz LM, Zhang Y, Smith RJ. Allelic variants of complement genes associated with dense deposit disease. J Am Soc Nephrol 2011, 22:1551–1559.

21. Jung S, Kang ES, Ni CS, Kim DW, Paik KH, Chang YS. Successful therapeutic plasma exchange in a 3.2-kg body weight neonate with atypical hemolytic uremic syndrome. J Clin Apher 2011, 26:162–165.

22. Magen D, Oliven A, Shechter Y, Elhasid R, Bar-Joseph G, Zelikovic I. Plasmapheresis in a very young infant with atypical hemolytic uremic syndrome. Pediatr Nephrol 2001, 16:87–90.

23. Geerdink LM, Westra D, van Wijk JA, Dorrestein EM, Lillen MR, Davin JC, Kornhoff M, Van Hoeck K, van der Vlugt A, van den Heuvel LP, van de Kar NC. Atypical hemolytic uremic syndrome in children: complement mutations and clinical characteristics. Pediatr Nephrol 2012, 27:1283–1291.

24. Besban N, Guhan B, Karpman D, Topaloglu R, Duzova A, Korkmaz E, Ozaltin F. Neonatal onset atypical hemolytic uremic syndrome successfully treated with eculizumab. Pediatr Nephrol 2013, 28:155–158.

25. Gruppo RA, Rother RP. Eculizumab for congenital atypical hemolytic-uremic syndrome. N Engl J Med 2009, 360:544–546.

26. Ariceta G, Amrizabalaga B, Aguirre M, Morteruel E, Lopez-Trascasa M. Eculizumab in the treatment of atypical hemolytic uremic syndrome in infants. Am J Kidney Dis 2012, 59:707–710.